How can you find QUATS that fit your requirements? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

How can you find QUATS that fit your requirements?

FeF Chemicals is a Novo Nordisk company that specialises in the supply of ingredients for the pharmaceutical and biopharmaceutical industries, such as and cGMP manufactured Quaternary Ammonium Compounds (usually referred to as Quats) e.g. Benzalkonium Chloride, Cetrimide and Cetrimonium Bromide and Insulin Human for cell culture media.

For our cGMP manufactured Quats we offer:

  • Global regulatory compliance
  • Manufacture in accordance with the highest GMP standards on the market, the ICH Guide Q7 for Active Pharmaceutical Ingredients
  • High purity products
  • Analyses according to multicompendial pharmacopoeias BP, Ph.Eur., USP/NF and JP
  • Regulatory documentation

As an approved supplier by a large number of global leading pharmaceutical companies, FeF Chemicals can assure full traceability and reliability of the raw materials. We have a well-developed management system, allowing tracing where the raw materials are used. We also have close contact with our suppliers and can meet with customer requested specifications. For us, reliability is not just in the system but also in the mindset of our employees.

QUALITY ASSURANCE
Our quality system meets DS/EN ISO 9001 and ICH’s cGMP Guide for Active Pharmaceutical Ingredients (ICH Q7). Uniform quality of finished products is ensured by our efficient quality control systems, computerised materials planning and rigorous laboratory quality control.

CUSTOMIZING QUATS
If the required product is not in the standard assortment, we can design customized products. Our flexible production process can meet customer demands for special chain length distribution and/or solutions of quats mixed in various ratios.

Contact details:
Email: fefinfo@fefchemicals.com
Web: www.fefchemicals.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
FindPharma Custom Search

Click here